| Cardiovascular mortality and heart failure (HF) hospitalizations remain high for those with HF with reduced ejection fraction (HFrEF). |
| New therapeutic options for HF are needed to improve outcomes. |
| Sodium–glucose cotransporter 2 inhibitors (SGLT2is) beneficially affect HFrEF. |
| SGLT2is improve HFrEF outcomes irrespective of type 2 diabetes status. |
| Dapagliflozin and empagliflozin are US Food and Drug Administration approved for the management of HFrEF; empagliflozin is also approved for HF with preserved ejection fraction. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.